Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10
|
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Triple-negative breast cancer
    Bartsch R.
    Ziebermayr R.
    Zielinski C.C.
    Steger G.G.
    Wiener Medizinische Wochenschrift, 2010, 160 (7-8) : 174 - 181
  • [32] New Perspectives in metastatic triple-negative Breast Cancer Approval of the first-in-class Antibody-Drug Conjugate Sacituzumab Govitecan
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (03) : 142 - 142
  • [33] Triple-Negative Breast Cancer
    Liedtke, Cornelia
    Schmutzler, Rita
    Schneeweiss, Andreas
    Loibl, Sybille
    Thill, Marc
    Heitz, Florian
    BREAST CARE, 2010, 5 (05) : 359 - 363
  • [34] Triple-negative breast cancer
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2020, 120 (08) : 22 - 23
  • [35] Triple-negative breast cancer
    Reinaldo D Chacón
    María V Costanzo
    Breast Cancer Research, 12
  • [36] Excellent effects and possible mechanisms of action of a new antibody–drug conjugate against EGFR-positive triple-negative breast cancer
    Dan-Dan Zhou
    Wei-Qi Bai
    Xiao-Tian Zhai
    Li-Ping Sun
    Yong-Su Zhen
    Zhuo-Rong Li
    Qing-Fang Miao
    Military Medical Research, 8
  • [37] Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth
    Cheung, Anthony
    Chenoweth, Alicia M.
    Johansson, Annelie
    Laddach, Roman
    Guppy, Naomi
    Trendell, Jennifer
    Esapa, Benjamina
    Mavousian, Antranik
    Navarro-Llinas, Blanca
    Haider, Syed
    Romero-Clavijo, Pablo
    Hoffmann, Ricarda M.
    Andriollo, Paolo
    Rahman, Khondaker M.
    Jackson, Paul
    Tsoka, Sophia
    Irshad, Sheeba
    Roxanis, Ioannis
    Grigoriadis, Anita
    Thurston, David E.
    Lord, Christopher J.
    Tutt, Andrew N. J.
    Karagiannis, Sophia N.
    CLINICAL CANCER RESEARCH, 2024, 30 (15) : 3298 - 3315
  • [38] Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
    Makhlin, Igor
    DeMichele, Angela
    CELL REPORTS MEDICINE, 2022, 3 (06)
  • [39] Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice
    Ziaei, Elmira
    de Paiva, Igor Moura
    Yao, Shih-Jing
    Sarrami, Nasim
    Mehinrad, Parnian
    Lai, Justine
    Lavasanifar, Afsaneh
    Kaur, Kamaljit
    MOLECULAR PHARMACEUTICS, 2023, 20 (07) : 3570 - 3577
  • [40] Anti-uPAR antibody drug conjugates for targeted therapy of triple-negative breast cancer
    Harel, Efrat
    McFarland, Jesse
    Bleck, Gregory
    Brain, Susie
    Drake, Penelope
    Rabuka, David
    Vantveer, Laura
    Craik, Charles
    CANCER RESEARCH, 2018, 78 (04)
12345